Siedlecki Jakob, Luft Nikolaus, Kook Daniel, Wertheimer Christian, Mayer Wolfgang J, Bechmann Martin, Wiltfang Rainer, Priglinger Siegfried G, Sekundo Walter, Dirisamer Martin
J Refract Surg. 2017 Aug 1;33(8):513-518. doi: 10.3928/1081597X-20170602-01.
To report the feasibility and outcomes of surface ablation after small incision lenticule extraction (SMILE).
In this retrospective evaluation of 1,963 SMILE procedures, 43 eyes (2.2%) were re-treated at three separate clinics. Of these, 40 eyes of 28 patients with a follow-up of at least 3 months were included in the analysis. During surface ablation, mitomycin C was applied for haze prevention.
Spherical equivalent was -6.35 ± 1.31 diopters (D) before SMILE and -0.86 ± 0.43 D before surface ablation. Surface ablation was performed after a mean of 9.82 ± 5.27 months and resulted in a spherical equivalent of 0.03 ± 0.57 D at 3 months (P < .0001). The number of patients within ±0.50 and ±1.00 D of target refraction increased from 22.5% to 80% and from 72.5% to 92.5%, respectively. Mean uncorrected distance visual acuity (UDVA) improved from 0.23 ± 0.20 to 0.08 ± 0.15 logMAR (P < .0001); 65% of patients gained at least one line. Corrected distance visual acuity (CDVA) remained unchanged with 0.01 ± 0.07 logMAR before versus -0.01 ± 0.05 logMAR after re-treatment (P = .99). Six eyes (15.0%) lost one line of CDVA, but final CDVA was 0.00 logMAR in four and 0.10 logMAR in two of these cases. The safety and efficacy indices were 1.06 and 0.90 at 3 months, respectively. Three of the four surface ablation profiles (Triple-A, tissue-saving algorithm, and topography-guided) resulted in equally good results, whereas enhancement with the aspherically optimized profile (ASA), used in two eyes, resulted in overcorrection (+1.38 and +1.75 D).
Combined with the intraoperative application of mitomycin C, surface ablation seems to be a safe and effective method of secondary enhancement after SMILE. Due to the usually low residual myopia, the ASA profile is not recommended in these cases. [J Refract Surg. 2017;33(8):513-518.].
报告小切口透镜切除术(SMILE)后表面切削的可行性及结果。
在对1963例SMILE手术的回顾性评估中,43只眼(2.2%)在3家不同诊所接受了再次治疗。其中,纳入分析的是28例患者的40只眼,随访时间至少3个月。在表面切削过程中,应用丝裂霉素C预防角膜 haze。
SMILE术前等效球镜度数为-6.35±1.31屈光度(D),表面切削术前为-0.86±0.43 D。表面切削平均在9.82±5.27个月后进行,3个月时等效球镜度数为0.03±0.57 D(P <.0001)。目标屈光度±0.50 D和±1.00 D范围内的患者数量分别从22.5%增加到80%和从72.5%增加到92.5%。平均裸眼远视力(UDVA)从0.23±0.20提高到0.08±0.15 logMAR(P <.0001);65%的患者至少提高了一行视力。矫正远视力(CDVA)保持不变,术前为0.01±0.07 logMAR,再次治疗后为-0.01±0.05 logMAR(P =.99)。6只眼(15.0%)的CDVA下降了一行,但其中4只眼最终CDVA为0.00 logMAR,2只眼为0.10 logMAR。3个月时的安全性和有效性指数分别为1.06和0.90。四种表面切削模式中的三种(Triple-A、节省组织算法和地形图引导)效果同样良好,而两只眼采用的非球面优化模式(ASA)强化导致了过矫(+1.38和+1.75 D)。
联合术中应用丝裂霉素C,表面切削似乎是SMILE术后二次强化的一种安全有效的方法。由于通常残余近视度数较低,这些病例不推荐使用ASA模式。[《屈光手术杂志》。2017;33(8):513 - 518。]